Eloxx Pharmaceuticals, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Eloxx Pharmaceuticals, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing increased operating expenses, significant net losses, and a substantial accumulated deficit, while also highlighting a recent public offering and Nasdaq uplisting.